Curcumin–Piperine/Curcumin–Quercetin/Curcumin–Silibinin dual drug-loaded nanoparticulate combination therapy: A novel approach to target and treat multidrug-resistant cancers

C. Moorthi, K. Kathiresan
{"title":"Curcumin–Piperine/Curcumin–Quercetin/Curcumin–Silibinin dual drug-loaded nanoparticulate combination therapy: A novel approach to target and treat multidrug-resistant cancers","authors":"C. Moorthi,&nbsp;K. Kathiresan","doi":"10.1016/j.jmhi.2012.10.005","DOIUrl":null,"url":null,"abstract":"<div><p>Curcumin is a functional food, which provides a wide range of health benefits including anti-cancer activity and considered as a suitable alternative for chemotherapeutic agents. However, cancer cells exhibit resistance to most chemotherapeutic agents including curcumin due to overexpression of adenosine triphosphate (ATP)-binding cassette transporter proteins in the cancer cell membrane, which decrease the intracellular concentration of chemotherapeutic agents. Similarly, most chemotherapeutic agents including curcumin experience lack of cancer cell targeting, lack of aqueous solubility, rapid systemic clearance, intestinal metabolism and hepatic metabolism. These limitations hinder the clinical usefulness of curcumin in the treatment of multidrug-resistant cancers. In this article, we propose curcumin–piperine, or curcumin–quercetin or curcumin–silibinin dual drug-loaded nanoparticulate combination therapy to target and treat multidrug-resistant cancers. The proposed dual drug-loaded nanoparticulate combination is expected to reverse the multidrug resistance, prevent the rapid systemic clearance, prevent the intestinal and the hepatic metabolism, increase the aqueous solubility, enhance the bioavailability, target the cancer cells, produce a synergistic anti-cancer effect and enhance the efficacy of curcumin in the treatment of multidrug-resistant cancers.</p></div>","PeriodicalId":100803,"journal":{"name":"Journal of Medical Hypotheses and Ideas","volume":"7 1","pages":"Pages 15-20"},"PeriodicalIF":0.0000,"publicationDate":"2013-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.jmhi.2012.10.005","citationCount":"73","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Medical Hypotheses and Ideas","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2251729412000328","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 73

Abstract

Curcumin is a functional food, which provides a wide range of health benefits including anti-cancer activity and considered as a suitable alternative for chemotherapeutic agents. However, cancer cells exhibit resistance to most chemotherapeutic agents including curcumin due to overexpression of adenosine triphosphate (ATP)-binding cassette transporter proteins in the cancer cell membrane, which decrease the intracellular concentration of chemotherapeutic agents. Similarly, most chemotherapeutic agents including curcumin experience lack of cancer cell targeting, lack of aqueous solubility, rapid systemic clearance, intestinal metabolism and hepatic metabolism. These limitations hinder the clinical usefulness of curcumin in the treatment of multidrug-resistant cancers. In this article, we propose curcumin–piperine, or curcumin–quercetin or curcumin–silibinin dual drug-loaded nanoparticulate combination therapy to target and treat multidrug-resistant cancers. The proposed dual drug-loaded nanoparticulate combination is expected to reverse the multidrug resistance, prevent the rapid systemic clearance, prevent the intestinal and the hepatic metabolism, increase the aqueous solubility, enhance the bioavailability, target the cancer cells, produce a synergistic anti-cancer effect and enhance the efficacy of curcumin in the treatment of multidrug-resistant cancers.

姜黄素-胡椒碱/姜黄素-槲皮素/姜黄素-水飞蓟素双重载药纳米粒联合治疗:一种靶向和治疗多药耐药癌症的新方法
姜黄素是一种功能性食品,它提供了广泛的健康益处,包括抗癌活性,被认为是化疗药物的合适替代品。然而,癌细胞对包括姜黄素在内的大多数化疗药物表现出耐药性,这是由于癌细胞膜中三磷酸腺苷(ATP)结合盒转运蛋白的过度表达,从而降低了化疗药物的细胞内浓度。同样,包括姜黄素在内的大多数化疗药物缺乏癌细胞靶向性、缺乏水溶性、快速全身清除、肠道代谢和肝脏代谢。这些限制阻碍了姜黄素在治疗多药耐药癌症中的临床应用。在本文中,我们提出姜黄素-胡椒碱,或姜黄素-槲皮素或姜黄素-水飞蓟素双重载药纳米颗粒联合治疗靶向和治疗多重耐药癌症。本文提出的双载药纳米粒联合有望逆转多药耐药,阻止全身快速清除,阻止肠道和肝脏代谢,增加水溶性,提高生物利用度,靶向癌细胞,产生协同抗癌作用,增强姜黄素治疗多药耐药癌症的疗效。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信